TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04247724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreational handball

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreational handball

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Study: NCT03088813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: IV
Study: NCT01545427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 200 mg bid for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo coated to match appearance of Gleevec identically.
Study: NCT00168454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A injected into detrusor on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A injected into detrusor on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A injected into detrusor on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A injected into detrusor on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A injected into detrusor on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) injected into detrusor on Day 1
Study: NCT02081599

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teneli (Teneligliptin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneli (Teneligliptin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study: NCT01103063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus chloroquine
Description: combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine
Description: Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
Study: NCT02045693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCV 3DAA FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-791325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Study: NCT01041287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is \>125/80 for the remaining 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is \>125/80 for the remaining 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is \>125/80 for the remaining 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is \>125/80 for the remaining 8 weeks
Study: NCT02446080

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk drink with probiotic culture
Description: The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk drink
Description: The control group was asked to drink 150 ml per day of dairy drinks.
Study: NCT04253587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabyrinthVR
Description: Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabyrinthVR
Description: Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabyrinthVR
Description: Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Games
Description: Commercially-available, narrative computer games marketed as cognitively enriching.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coherence
Description: Head-mounted display virtual reality game designed to present an adaptive rhythm training routine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet
Description: Tablet computer playing Labyrinth VR game but in 2.5D
Study: NCT02979223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid
Description: sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid
Description: sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group
Study: NCT03626545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
Study: NCT03057080

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous transluminal angioplasty (PTA)
Description: The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
Study: NCT01701934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500 mcg, oral, once daily for 6 months
Study: NCT02724904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Standard Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Standard Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV Bolus
Study: NCT03733171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLATELET RICH PLASMA
Description: PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
Study: NCT01701934

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo pill daily, for 6 months
Study: NCT02078388

Intervention type: DRUG
Intervention: Doxorubicin
Study: NCT04306536

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortifit®
Description: Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
Study: NCT00347386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Zinc (zinc sulphate)
Description: Dissolvable tablet 10 mg. Once daily during the illness

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, once daily
Study: NCT02258763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Oral antibiotic for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Oral antibiotic for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
Study: NCT02552121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (HuMax-TF-ADC)
Study: NCT05532891

Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
Study: NCT01649986

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-pharmacologic intervention
Description: Diet and physical exercise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceuticals (Armolipid Plus)
Description: Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
Study: NCT01019850

Intervention type: DRUG
Group type: OTHER
Intervention: Vorinostat
Description: Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
Study: NCT01555307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Typical range of motion and muscle strengthening exercises, and balance exercises
Description: Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.

Intervention type: OTHER
Group type: OTHER
Intervention: Typical group
Description: Seven typical exercises, 10 times each, 3 times a day
Study: NCT00237809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: D-serine (30 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: D-serine (30 mg/kg)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Retraining (CRT)
Description: Cognitive retraining therapy (CRT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Retraining (CRT)
Description: Cognitive retraining therapy (CRT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo D-serine Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo D-serine Drug
Study: NCT01019850

Intervention type: RADIATION
Group type: OTHER
Intervention: 131- I Metaiodobenzylguanidine
Description: Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral Blood Stem Cell Infusion
Description: Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
Study: NCT04247724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Study: NCT01673204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: dosage of 0.5mcg administered orally once daily for 12 month
Study: NCT00592332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: 1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
Study: NCT00372697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide acetate 30 mg suspension
Description: Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide acetate 30 mg suspension
Description: Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
Study: NCT02787915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC1-CTL
Description: Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
Study: NCT01549873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol adjusted to maintain the bispectral index at 40-60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane adjusted to maintain the bispectral index at 40-60.
Study: NCT00946907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
Study: NCT03247127

Intervention type: RADIATION
Group type: OTHER
Intervention: Hippocampal avoidance whole brain radiotherapy
Description: Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
Study: NCT01841255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthpiece (Umox)
Description: Device used to perform preoxygenation in the operating room context

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthpiece (Umox)
Description: Device used to perform preoxygenation in the operating room context

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthpiece (Umox)
Description: Device used to perform preoxygenation in the operating room context

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: facemask
Study: NCT01939366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 100 µg
Description: Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 300 µg
Description: Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 600 µg
Description: Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo will be matched to pregabalin and cebranopadol.
Study: NCT04349956

Intervention type: DRUG
Intervention: UBX0101 or placebo
Description: This is an observational study. No intervention is administered.
Study: NCT01320592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT00237809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Retraining Placebo
Description: Cognitive retraining therapy (CRT) control
Study: NCT03748459

Intervention type: OTHER
Intervention: Closure with Permanent Suture
Description: Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.

Intervention type: OTHER
Intervention: Closure with Resorbable Suture
Description: Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
Study: NCT01673204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01734967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle based CLE
Description: EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Description: Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
Study: NCT01787435

Intervention type: DRUG
Intervention: Risk of asthma in offspring
Description: Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy

Intervention type: DRUG
Intervention: Risk of asthma in offspring
Description: Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy
Study: NCT04778696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PASO Pacemapping
Description: Using the PASO pacemapping visualisation module of CARTO3

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pacemapping
Description: without visualisation in 3D mapping
Study: NCT04087967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine plus HAAG regimen
Description: Decitabine:20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~16,intravenous infusion; Aclarubicin:10mg/d, d3\~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicine plus Cytarabine regimen
Description: Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
Study: NCT03396406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF)
Description: received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermocoagulation
Description: received sole CRF at 70°C for 270 s